Paroxetine Mesylate: Multi-Target SSRI with Oncology Potential

Executive Summary: Paroxetine Mesylate (CAS No. 217797-14-3) is a selective serotonin reuptake inhibitor that binds SERT with high affinity (~70 pM) and inhibits serotonin reuptake (Kowalska et al., 2021). It also inhibits CYP2D6 (Ki = 0.065 μM), CYP2B6, and several kinases including GRK2, MET, and ERBB3 in the nanomolar to micromolar range. In colorectal cancer cell lines, it blocks proliferation and induces apoptosis with IC50 values of 7–26 μM (see discussion). Paroxetine Mesylate is used clinically for psychiatric disorders at 20–60 mg/day, with dual reuptake inhibition observed at ≥40 mg/day (Kowalska et al., 2021). APExBIO provides Paroxetine Mesylate (SKU: C8698) for research use, supporting studies in neuroscience, oncology, and translational medicine (product page).

Biological Rationale

Paroxetine Mesylate is a synthetic compound in the SSRI class, designed to elevate synaptic serotonin levels by blocking its reuptake transporter (SERT). This mechanism underlies its efficacy in treating major depressive disorder, obsessive-compulsive disorder, and social anxiety disorder (Kowalska et al., 2021). Recent evidence reveals broader pharmacological actions: Paroxetine Mesylate inhibits cytochrome P450 enzymes, kinases such as GRK2, and receptor tyrosine kinases including MET and ERBB3, expanding its utility to oncology and biomarker research (see contrast). Its molecular profile allows cross-domain applications, from psychiatric care to cancer cell growth inhibition and cardiac biomarker studies in epilepsy models.

Mechanism of Action of Paroxetine Mesylate

As an SSRI, Paroxetine Mesylate exhibits nanomolar affinity for the serotonin transporter, with a reported binding constant of 70.2±0.6 pM (Kowalska et al., 2021). It stabilizes SERT in an outward-occluded state, preventing serotonin reuptake and increasing extracellular serotonin concentrations. At higher doses (≥40 mg/day), dual inhibition of norepinephrine reuptake has been observed (Kowalska et al., 2021). Paroxetine Mesylate further acts as a potent inhibitor of CYP2D6 (Ki = 0.065 μM) and a moderate inhibitor of CYP2B6 (Ki = 1.03 μM), affecting drug metabolism pathways. It also inhibits GRK2 (IC50 = 1.4 μM), MET, ERBB3, KIT, and JAK kinases, implicating roles in signal transduction, cell proliferation, and receptor desensitization (see molecular insights). Notably, Paroxetine Mesylate displays affinity for the Ebola virus glycoprotein (pKi ~3.19), suggesting antiviral research applications (Kowalska et al., 2021).

Evidence & Benchmarks

• High-affinity SERT inhibition: Paroxetine Mesylate binds SERT at 70.2±0.6 pM, surpassing many other SSRIs (Kowalska et al. 2021).
• CYP2D6 inhibition: Ki = 0.065 μM; CYP2B6 inhibition: Ki = 1.03 μM (Kowalska et al. 2021).
• GRK2 inhibition: IC50 = 1.4 μM (Kowalska et al. 2021).
• Inhibition of MET and ERBB3 kinases, with activity in nanomolar–micromolar range (internal oncology review).
• Anti-colorectal cancer activity: Inhibits HCT116 and HT29 proliferation and colony formation, IC50 = 7–26 μM; induces apoptosis; blocks 3D spheroid formation (oncology application).
• Clinically, oral dosing achieves steady-state plasma levels in 4–14 days; metabolized via hepatic CYP2D6 (Kowalska et al. 2021).
• Veterinary and translational models: Used in canine aggression, epilepsy biomarker research, and baboon SUDEP studies (epilepsy biomarker study).

This article extends prior discussions such as 'Paroxetine Mesylate: Multi-Target Mechanisms and Translational Impact' by integrating new quantitative kinase and CYP inhibition data and clarifying anti-cancer benchmarks.

Applications, Limits & Misconceptions

Paroxetine Mesylate is established for major depression, OCD, and social anxiety, with off-label use in pediatric psychiatric disorders and menopausal vasomotor symptoms (Kowalska et al., 2021). Its kinase and P450 inhibition profile underpins new oncology and drug-drug interaction research. The compound is used in colorectal cancer xenograft models and cardiac biomarker studies in epileptic baboons (see translational review). However, its clinical anti-cancer efficacy remains investigational. For research, high-purity Paroxetine Mesylate (SKU: C8698) is available from APExBIO.

Common Pitfalls or Misconceptions

• Paroxetine Mesylate is not a broad-spectrum kinase inhibitor; activity is specific to select kinases (e.g., MET, ERBB3, GRK2).
• Clinical anti-cancer use is not established; current data derive from in vitro and preclinical models.
• Dual reuptake inhibition (serotonin/norepinephrine) requires doses ≥40 mg/day; standard doses affect only serotonin.
• Metabolism via CYP2D6 can lead to drug-drug interactions; genetic polymorphisms affect exposure.
• Solution stability is limited; storage at -20°C is recommended, and long-term solution storage should be avoided.

Workflow Integration & Parameters

Protocol Parameters

• In vitro anti-cancer assays: Use Paroxetine Mesylate at 7–26 μM for HCT116 and HT29 cell proliferation/apoptosis studies (see in vitro data).
• Xenograft models: Reference published dosing regimens and titrate based on animal model and study design.
• Psychiatric dosing: Typical oral dose: 20–60 mg per day; dual reuptake inhibition at ≥40 mg/day (clinical review).
• Enzyme inhibition: CYP2D6 inhibition observed at sub-micromolar concentrations; adjust co-administered drug metabolism assays accordingly.
• Storage: Store solid Paroxetine Mesylate at -20°C; avoid long-term storage of dissolved solutions (product specification).

Conclusion & Outlook

Paroxetine Mesylate exemplifies a multi-target research tool, functioning as a potent selective serotonin reuptake inhibitor, a cytochrome P450 modulator, and a kinase inhibitor with implications for oncology and translational studies. Its established neuropsychiatric profile, combined with emerging evidence for anti-colorectal cancer activity and kinase targeting, highlights its cross-domain relevance. Future research should clarify its in vivo anti-cancer efficacy and expand mechanistic studies into kinase selectivity and drug-drug interaction risk. APExBIO continues to supply high-purity Paroxetine Mesylate to support rigorous research across neuroscience, oncology, and systems pharmacology.

Why this cross-domain matters, maturity, and limitations

The ability of Paroxetine Mesylate to inhibit both neurotransmitter reuptake and oncogenic kinase pathways bridges psychiatry and oncology research, facilitating translational studies into mechanisms of cell signaling, drug resistance, and biomarker discovery. However, while in vitro and preclinical results are promising, clinical translation for oncology remains exploratory and should be interpreted with caution until large-scale trials are available (Kowalska et al., 2021).